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OBJECTIVE—Many genetic variants have been associated with
glucose homeostasis and type 2 diabetes in genome-wide associa-
tion studies. Zinc is an essential micronutrient that is important
for b-cell function and glucose homeostasis. We tested the hypoth-
esis that zinc intake could inﬂuence the glucose-raising effect of
speciﬁc variants.
RESEARCH DESIGN AND METHODS—We conducted a 14-
cohort meta-analysis to assess the interaction of 20 genetic variants
known to be related to glycemic traits and zinc metabolism with
dietary zinc intake (food sources) and a 5-cohort meta-analysis
to assess the interaction with total zinc intake (food sources
and supplements) on fasting glucose levels among individuals of
European ancestry without diabetes.
RESULTS—We observed a signiﬁcant association of total zinc
intake with lower fasting glucose levels (b-coefﬁcient 6 SE per
1 mg/day of zinc intake: 20.0012 6 0.0003 mmol/L, summary
P value = 0.0003), while the association of dietary zinc intake
was not signiﬁcant. We identiﬁed a nominally signiﬁcant interac-
tion between total zinc intake and the SLC30A8 rs11558471 vari-
ant on fasting glucose levels (b-coefﬁcient 6 SE per A allele for
1 mg/day of greater total zinc intake: 20.0017 6 0.0006 mmol/L,
summary interaction P value = 0.005); this result suggests a stronger
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ORIGINAL ARTICLE
inverse association between total zinc intake and fasting glucose
in individuals carrying the glucose-raising A allele compared with
individuals who do not carry it. None of the other interaction
tests were statistically signiﬁcant.
CONCLUSIONS—Our results suggest that higher total zinc in-
take may attenuate the glucose-raising effect of the rs11558471
SLC30A8 (zinc transporter) variant. Our ﬁndings also support evi-
dence for the association of higher total zinc intake with lower
fasting glucose levels. Diabetes 60:2407–2416, 2011
Chronic elevations in fasting or postprandial glu-cose levels are the cardinal features of type 2diabetes (T2D), a common complex diseasecaused by the interplay of genetic and lifestyle
factors. Genome-wide association studies (GWAS) have
identiﬁed genetic loci reproducibly associated with glyce-
mic traits or T2D (1,2). These studies improved our under-
standing of the mechanisms underlying impaired glucose
homeostasis and T2D, potentially aiding the development of
novel and individualized medical therapies (3,4).
Modiﬁable lifestyle factors, such as diet and physical
activity, inﬂuence glucose homeostasis and thus represent
important targets for T2D prevention and management (5).
Zinc is an essential trace element found in most foods that
facilitates catalytic, structural, and transcriptional actions
within cells (6). Zinc is a critical component of the catalytic
site of .300 enzymes, including pancreatic carboxypep-
tidases and RNA polymerases; coordinates with protein
domains; facilitates protein folding; produces structures
such as zinc ﬁngers; and regulates the expression of
metallothioneins (7–9). Zinc is necessary in b-cells for insulin
crystallization in hexamers (10). Moreover, it is cosecreted
with insulin and exerts insulinomimetic and antioxidant
actions and participates in the regulation of b-cell mass
(11,12). Zinc homeostasis is impaired in animal models of
diabetes and in humans with diabetes (13,14). Indeed, zinc
supplementation studies in animal models support a pro-
tective effect of zinc against T2D, and in humans plasma
levels of zinc are inversely associated with the risk of T2D
(13). Nevertheless, a causal link between zinc and T2D
in humans is not well established. Data from population-
based studies indicate that dietary and total zinc intake
(food sources and supplements) may reduce T2D risk
(15–17), but the few intervention studies investigating
the effect of zinc supplementation on glucose meta-
bolism, insulin homeostasis, or T2D risk have yielded
inconsistent results (13,18). Therefore, although zinc
supplementation is a potential therapeutic and pre-
ventive target for T2D, additional studies are needed
before population-wide recommendations regarding zinc
intake can be advocated.
Knowledge of gene-environment interactions may en-
hance our understanding of disease etiology and patho-
genesis, as well as help personalize interventions. We
recently have demonstrated a favorable association of
whole-grain intake with fasting glucose and insulin and
observed a potential interaction between the rs780094
GCKR variant and whole-grain intake on fasting insulin
concentrations (19). Zinc intake previously has been shown
to interact with genetic variants in relation to chronic dis-
eases and inﬂammatory biomarkers (8,20–22) but not in the
context of glycemic traits.
To address these gaps in the literature, we conducted a
meta-analysis that included 14 cohorts, totaling up to 45,821
participants, to test the hypothesis that zinc intake modiﬁes
the cross-sectional association between fasting glucose
levels and genetic variants known to be related to glycemia
and zinc metabolism (2) in individuals of European descent
without T2D.
RESEARCH DESIGN AND METHODS
The study sample for the current cross-sectional meta-analysis was combined
from 14 cohort studies (Supplementary Table 1), the majority of which are
included in the CHARGE (Cohorts for Heart and Aging Research in Genome
Epidemiology) Consortium (23) and/or the Meta-Analyses of Glucose and
Insulin-Related Traits Consortium (MAGIC). Ethical approval was obtained by
local bioethical committees, and all participants provided signed informed
consent. Participants included in the current analyses did not have diabetes
(deﬁned as diagnosed self-reported diabetes and/or fasting glucose levels
$7 mmol/L and/or use of antidiabetes medications) and had dietary data that
met quality-control criteria (Supplementary Table 1).
Anthropometric and blood glucose measurements. We calculated BMI
as measured weight divided by the square of measured height (kg/m2) in all
cohorts. We determined blood glucose levels in fasting plasma samples, with
the exceptions of participants in the Family Heart Study (FamHS), the Car-
diovascular Health Study (CHS), the Rotterdam Study, and the Atherosclerosis
Risk in Communities (ARIC) study, for whom we used fasting serum samples,
and the Malmö Diet and Cancer (MDC) study, in which we used fasting whole-
blood samples (Supplementary Table 1).
Dietary assessment and zinc intake estimation. Dietary data were col-
lected (Supplementary Table 1) and processed to estimate the mean daily
dietary zinc intake using an appropriate nutrient/food composition database
for each cohort (Supplementary Table 1). Supplemental zinc intake (singly or
in a multiple-nutrient supplement) was recorded in ﬁve cohorts and was
quantiﬁed in milligrams per day. Total zinc intake was calculated as the sum of
dietary and supplemental intake.
Genotyping and imputation. Twenty single nucleotide polymorphisms
(SNPs) were included in the current meta-analysis (Tables 2 and 3 and Sup-
plementary Data). Among these, 18 SNPs were recently associated with fast-
ing glucose and/or fasting insulin levels in a large GWAS and meta-analysis
study reported by the MAGIC (2). Two SNPs (rs10493846 and rs11167682)
were selected for their potential role in zinc metabolism (24,25). A detailed
description of the genotyping methods used for each study is provided in
Supplementary Table 1.
Statistical analysis. All cohort-speciﬁc statistical analyses followed a uniform
analytical plan. Linear regression models were applied to estimate the mag-
nitude of the cross-sectional association of dietary and total zinc intake with
fasting glucose levels, as well as the magnitude of the ﬁrst-order SNP inter-
actions (assuming an additive model) with dietary and total zinc intake on
fasting glucose levels. All models were adjusted for age, sex, ﬁeld center (in the
ARIC study, the CHS, the FamHS, the Health Aging and Body Composition
[Health ABC] study, and the Aging In the CHIANTI area [InCHIANTI] study),
and family structure by principal components (in the Framingham Heart Study
[FHS] and the FamHS). Associations were further adjusted for BMI levels to
limit potentially confounding effects of adiposity.
Meta-analysis. The sample size for the association analysis of dietary zinc
intake (food sources) with fasting glucose was 46,021 participants. The
sample size for the interaction analysis between dietary zinc intake and SNPs
ranged from 27,010 to 45,821 participants. Corresponding association and
interaction analyses of total zinc intake (food sources and supplements)
included 34,533 and 18,158 to 34,333 participants, respectively. We performed
power calculations using Quanto version 1.2 (http://hydra.usc.edu/gxe). Ac-
cordingly, at 80% power, P , 0.05 detected a difference of 0.0013 mmol/L on
fasting glucose levels per 1 mg/day higher dietary zinc intake and 0.0008
mmol/L in fasting glucose levels per 1 mg/day higher total zinc intake. At the
same power and critical a, our study was large enough to detect a minimal
interaction effect of 0.0031 mmol/L between dietary zinc intake (per 1 mg/day)
and SNPs (per effect allele) on fasting blood glucose levels. Our study had
80% power to detect a minimal interaction effect of 0.0012 mmol/L be-
tween total zinc intake (per 1 mg/day) and SNPs (per effect allele) on fasting
glucose levels.
We conducted an inverse variance-weighted, ﬁxed–effect, meta-analyses
on summary statistics provided by each cohort (METAL software, www.sph.
umich.edu/csg/abecasis/metal/, for SNPs and zinc intake-interaction effects;
SPSS 18.0, SPSS, Chicago, IL, for zinc-intake effects). Heterogeneity was
estimated by Cochran’s Q statistic and quantiﬁed by the I2 statistic (26).
Statistical signiﬁcance was deﬁned as a P value #0.0025 (0.05 per 20 tests),
after Bonferroni correction for multiple testing.
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RESULTS
The descriptive characteristics of the 14 participating cohorts
are summarized in Table 1. Mean dietary zinc intake (food
sources) was comparable across cohorts (Fig. 1), ranging
from 8.3 to 12.4 mg/day, with an average dietary zinc intake
of 10.3 mg/day. Mean total zinc intake (food sources and
supplements) ranged from 8.7 to 17.3 mg/day, resulting in
an average total zinc intake of 13.8 mg/day.
TABLE 1
Descriptive characteristics of the 14 participating cohorts
Cohorts N Age (years)
Women
(%)
Fasting
glucose
(mmol/L)*
Dietary zinc
intake
(mg/day)
Total zinc
intake
(mg/day)
Zinc
supplement
users (%)
BMI
(kg/m2)
FHS 5,835 46.1 (11.5) 54.7 5.2 (0.5) 12.4 (5.2) 15.9 (11.2) 21.8 26.7 (5.0)
MDC 4,867 57.5 (5.9) 60.0 5.5 (0.5) 11.4 (3.4) 13.4 (6.1) 18.1 25.4 (3.8)
FamHS 2,094 50.1 (13.1) 55.5 5.2 (0.5) 11.4 (5.6) — — 27.3 (5.1)
CHS 1,755 71.2 (4.5) 63.8 5.1 (0.6) 11.2 (6.3) 17.3 (16.5) 26.0 26.4 (4.3)
InCHIANTI 1,071 67.7 (15.8) 56.3 4.8 (0.6) 10.9 (3.4) — 0 27.0 (4.1)
Rotterdam Study 2,345 65.4 (6.6) 58.3 5.5 (0.5) 10.7 (2.7) — 0 26.5 (4.0)
ARIC 6,088 60.2 (5.6) 54.4 5.5 (0.6) 10.5 (4.5) 13.9 (11.0) 18.5 27.6 (5.0)
PIVUS† 770 70.2 (0.2) 51.0 5.0 (0.6) 10.4 (2.6) — — 26.8 (4.1)
Health ABC 1,263 74.8 (2.9) 50.6 5.1 (0.6) 10.3 (5.1) — — 26.2 (4.0)
Fenland Study 1,071 45.0 (7.3) 56.1 4.9 (0.5) 9.4 (3.0) — — 27.0 (4.9)
ULSAM‡ 931 71.0 (0.6) 0.0 5.4 (0.6) 9.3 (2.4) — — 26.0 (3.2)
GHRAS§ 856 71.8 (7.5) 71.2 5.8 (1.6) 8.9 (2.7) — 0 29.7 (4.8)
GENDAI‖ 1,087 11.2 (0.7) 53.2 4.8 (0.5) 8.7 (3.4) — 0 20.0 (3.4)
GLACIER¶ 15,988 52.3 (8.8) 60.2 5.4 (0.6) 8.3 (3.0) 8.7 (3.3) 8.3 25.9 (4.1)
Data are means (SD).—, not available. *Fasting glucose was measured at the baseline examination (when dietary assessment was conducted)
in all cohorts, except for the MDC study and Rotterdam Study, in which fasting glucose was measured ~7 months and 6 years, respectively,
after the dietary assessment and for the ARIC study, in which examination “three” dietary/supplement data and glucose measurements were used.
†Prospective Investigation of the Vasculature in Uppsala Seniors; ‡Uppsala Longitudinal Study of Adult Men; §Greek Health Randomized Aging
Study; ‖Gene-Diet Investigation on Childhood Obesity; ¶Gene-Lifestyle Interactions and Complex Traits Involved in Elevated Disease Risk.
FIG. 1. Mean dietary and total zinc intake across cohorts. Values are presented as means (SD) and expressed as milligrams per day of dietary (food
sources) and total (food sources and supplements) zinc intake. ●, dietary zinc; ○, total zinc.
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FIG. 2. Forest plots of the effect associations of zinc intake with fasting glucose. A: The effect association of total zinc (food sources and sup-
plements) intake (per 1 mg/day) (summary P value = 0.0003, n = 34,533). B: Effect association of dietary zinc (food sources) intake (per 1 mg/day)
(summary P value = 0.52, N = 46,021). Fasting blood glucose is expressed in micromoles per liter, and all associations are adjusted for age and sex,
ﬁeld center (in the CHS, the InCHIANTI study, the ARIC study, and the Health ABC study), and family structure by principal components (in the
FHS and the FamHS).
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Association of zinc intake and genetic variants with
fasting glucose levels. We observed a signiﬁcant associa-
tion of total zinc intake with lower fasting glucose levels
(summary P value = 0.0003), with an estimated 0.0012 mmol/L
lower fasting glucose concentration per 1 mg greater daily
total zinc intake (Fig. 2A). When we additionally adjusted
for BMI levels, the magnitude of the association was slightly
attenuated (b-coefﬁcient 6 SE: 20.0009 6 0.0003 mmol/L
fasting glucose per 1 mg/day greater total zinc intake, sum-
mary P value = 0.0037). In contrast, we did not observe a
signiﬁcant association of dietary zinc intake with fasting glu-
cose levels (Fig. 2B); however, we observed that the mag-
nitude and direction of cohort-speciﬁc associations varied
notably. After additional adjustments for BMI levels, the
association between dietary zinc intake and fasting glu-
cose levels remained nonsigniﬁcant (b-coefﬁcient 6 SE:
20.0005 6 0.0006, summary P value = 0.43).
In the meta-analysis, 16 of 20 SNPs were signiﬁcantly as-
sociated with fasting glucose levels (Supplementary Table 2).
This was consistent with previous published data from the
MAGIC (2) that included, as a subsample, roughly one-half
of all participants included in the current meta-analysis
(Supplementary Table 1).
Interaction of zinc intake and genetic variants on
associations with fasting glucose levels.We investigated
the interactions between the genetic variants and total
zinc intake (available in ﬁve cohorts; Supplementary Ta-
ble 3), and the strongest interaction we observed was for
rs11558471 in SLC30A8 (b-coefﬁcient 6 SE per A allele
of 1 mg/day greater total zinc intake: 20.0017 6 0.0006;
summary interaction P value = 0.005) (Table 2 and Fig. 3).
This interaction coefﬁcient indicates that the glucose-
raising effect of the risk allele (A) of rs11558471 dimin-
ishes as total zinc intake increases (per 1 mg/day), with
the strongest inverse association between glucose and
total zinc intake seen in individuals carrying both copies
of the risk allele. When we applied additional adjustment
for BMI, the interaction between rs11558471 and total
zinc intake with fasting glucose was slightly attenuated
(b-coefﬁcient6 SE:20.00146 0.0006; summary interaction
P value = 0.01).
Because the interaction effects reported above may be
inﬂuenced by the total amount and source of zinc (i.e., di-
etary or supplemental), we proceeded by stratifying the
interaction analyses by zinc supplement use (i.e., zinc sup-
plement users and nonusers) (Fig. 4). As hypothesized, the
magnitude of the interaction between total zinc intake and
SLC30A8 variant was weaker among zinc-supplement
nonusers (b-coefﬁcient 6 SE: 20.0006 6 0.0014; summary
P value = 0.65) compared with zinc-supplement users
(b-coefﬁcient 6 SE: 20.0024 6 0.0009; summary P value =
0.008).
Few of the additional tests of gene-times-zinc interac-
tions yielded noteworthy results (Tables 2 and 3). Of these,
the most statistically signiﬁcant tests of interaction were
observed for the rs340874 PROX1 (for total zinc intake)
(Table 2), rs2191349 DGKB/TMEM195, and rs174550 FADS1
variants (for dietary zinc intake) (Table 3 and Supplemen-
tary Fig. 2; cohort-speciﬁc estimates shown in Supplemen-
tary Table 4), although none of these P values withstood
correction for multiple testing.
DISCUSSION
Given the important role of zinc in b-cell function and in-
sulin homeostasis (12), we hypothesized that zinc intake
might modify the effects of previously discovered glucose-
raising genetic loci (2), many of which are thought to
inﬂuence b-cell function. To test this hypothesis, we con-
ducted a large-scale meta-analysis of up to 14 cohorts in
which we assessed the interaction between zinc intake and
glucose-associated genetic variants on fasting glucose
levels among individuals without T2D.
FIG. 3. Forest plot of the interaction between SLC30A8 rs11558471 and total zinc intake on fasting glucose. The rs11558471 effect is expressed
per A allele, total zinc (food sources and supplements) intake per 1 mg/day, and fasting blood glucose in micromoles per liter. Associations are
adjusted for age and sex, ﬁeld center (in the CHS and the ARIC study), and family structure by principal components (in the FHS) (summary
P value = 0.0051, N = 34,150).
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The strongest interaction effect was detected for the
SLC30A8 rs11558471 variant and total zinc intake (food
sources and supplements) on fasting glucose levels. We
estimated that, for individuals with the A/G genotype (i.e.,
one glucose-raising allele), an average daily total zinc intake
of 14 mg (observed in our study) is associated with a 0.024
mmol/L lower glucose concentration than seen in individ-
uals with the G/G genotype (i.e., two non–glucose-raising
alleles). Concordantly, in individuals with both copies of the
risk allele (i.e., A/A genotype), the magnitude of this asso-
ciation was doubled (i.e., 0.048 mmol/L). An average daily
total zinc intake of 14 mg could be achieved by a nutrient
supplement (~10 mg zinc) plus an average serving of red
meat or ﬁsh/seafood (~3 ounces) or three average servings
of dairy products (~2 cups of milk per yogurt and 3 ounces
of cheese). Further investigation of this interaction effect
showed that it was more evident among zinc supplement
users than among nonusers. We also observed a signiﬁcant
association of total zinc intake, but not dietary zinc intake
alone, with lower fasting glucose levels. None of the other
investigated interactions between zinc intake (dietary
or total) and variants were statistically signiﬁcant after
multiple-testing adjustment.
Current ﬁndings in the context of gene-environment
interaction investigations. The SLC30A8 gene encodes
the newly characterized ZnT8 zinc transporter (27). Zinc
homeostasis depends on two families of transporters: the
ZIP (SLC39) family regulating cellular zinc inﬂux and the
ZnT (SLC30) family regulating efﬂux (28). It has been
shown that the ZnT8 transporter is primarily expressed in
b-cells and colocalizes with insulin-containing secretory
granules (29). Alterations in ZnT8 expression strongly
modulate insulin secretion (29,30). Moreover, it has re-
cently been shown that ZnT8 b-cell–speciﬁc knockout
(Znt8KO) mice are glucose intolerant have reduced b-cell
zinc accumulation, have atypical insulin granules, have
reduced ﬁrst-phase glucose-stimulated insulin secretion,
have reduced insulin-processing enzyme transcripts, and
have increased proinsulin levels (14). Furthermore, a ge-
netic variant (rs13266634) in SLC30A8 has been reliably
associated with fasting glucose levels and T2D risk in
several GWAS (31–34). Of interest, observations suggest
that this variant impairs islet ZnT8 expression, insulin
secretion, or glucose homeostasis (35–37). In addition, this
variant is associated with the production of a less active
zinc transporter protein, suggesting less efﬁciency of zinc
FIG. 4. Forest plots of the SLC30A8 rs11558471 interaction with zinc intake on glucose, by zinc supplement use. The rs11558471 effect is
expressed per A allele, zinc intake per 1 mg/day, and fasting blood glucose in micromoles per liter. Associations are adjusted for age and sex, ﬁeld
center (in the CHS and the ARIC study), and family structure by principal components (in the FHS) (summary P value = 0.0077, N = 4,986 for zinc
supplement users and summary P value = 0.65, n = 29,164 for zinc supplement nonusers).
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accumulation and insulin crystallization (38). It recently has
been demonstrated that the same variant does not affect
insulin secretion from human islets as well as islet expres-
sions of SLC30A8 (39). It is noteworthy that rs13266634 is
in strong linkage disequilibrium with rs11558471 (r2 = 0.96),
included in the current study. Additional studies on these
topics are important to provide evidence that variation at
SLC30A8 inﬂuences the regulation of zinc transporter ac-
tivity or the modulation of islet zinc content; this would
support the biological plausibility of the statistical inter-
action we report here.
Current ﬁndings in the context of dietary epidemio-
logical investigations. Our meta-analysis revealed a sig-
niﬁcant inverse association between total zinc intake and
fasting glucose levels. Of interest, we did not observe this
association when only zinc derived from food sources
was considered. This observation may be attributable
to a number of factors, including differences in the bio-
availability of dietary zinc compared with zinc supple-
ments (40), a threshold effect of zinc intake on fasting
glucose levels, or because when dietary and supple-
mental zinc are combined the wider trait variance
affords greater statistical power to detect associations
and interactions. The latter also is based on the power
calculations we performed (RESEARCH DESIGN AND METHODS).
Moreover, the different dietary assessment tools used to
assess dietary zinc intake across the participating cohorts
may have varied in precision to a greater extent than
when used to assess supplemental zinc intake. However,
potential confounding lifestyle characteristics associated
with supplement use were not considered in the current
study.
Our ﬁndings are in line with results from a large 24-
year prospective study among women, demonstrating
a signiﬁcant association between total zinc intake and
lower risk of T2D (17). In the same study, but in contrast
to our results, dietary zinc intake also was associated
with a lower risk of T2D after multiple adjustments for
dietary and nondietary factors (17). In a cross-sectional
study of an Asian-Indian population (16), dietary zinc
intake was associated with a lower prevalence of T2D
and the metabolic syndrome. However, another study of
Chinese adults did not observe a relationship between
dietary zinc intake and risk of hyperglycemia (15).
However, it is worth mentioning that in the current study
we focused on fasting glucose levels in subjects without
T2D, as opposed to the prevalence of T2D in the refer-
enced studies.
Strengths and limitations. The strengths of the current
work include the large samples, the availability of stan-
dardized exposure and outcome data, and the use of a
uniform analytical plan prior to meta-analysis. The advan-
tages of meta-analyses like ours over individual studies or
literature-based meta-analysis include improved power to
detect interaction effects and the minimization of recall bias
and publication bias (41,42).
We selected the majority of the genetic variants included
in our meta-analysis on the basis of the results of GWAS
for genetic main effects on insulin or glucose traits (2).
This approach is convenient, and one can be conﬁdent that
the genetic variants are reliably associated with the traits
of interest, which is rarely the case with conventional bi-
ologic candidate-gene studies. Nevertheless, it may be that
the variants that reach genome-wide signiﬁcance in main-
effect GWAS are less likely to interact with environmental
factors because such interactions tend to weaken the
statistical signiﬁcance of the main effects (43). Although
the effect estimates observed here are indeed small in
magnitude, it is important to bear in mind that these effects
are likely to be underestimated, given that the observed
genetic loci may not be causal and because the methods of
determining usual zinc intake are imprecise. Our approach
does not preclude that other genetic variants not previously
known to be associated with glycemic traits might interact
with zinc intake.
As with all epidemiological studies assessing dietary
intake, systematic measurement error in the diet exposure
could have biased our results. However, there currently
is no satisfactory biomarker for the assessment of di-
etary zinc intake, and even though plasma zinc concen-
tration seems to be a reliable marker of zinc status, it
has limited sensitivity in the normal range of zinc intake
(44,45). The issues of dietary assessment validity versus
cost-effectiveness in population-based studies have been
widely discussed elsewhere (46,47), but it is unlikely that
a glucose-associated genotype is associated with a ten-
dency to misreport dietary intake. Furthermore, we did
not assess interactions of zinc with other nutrients; such
interactions might inﬂuence the bioavailability of zinc
(40). Systematic measurement error in the estimation of
dietary exposures in gene-environment interaction studies
could bias the estimation of the dietary main effect and
lead to underestimates of the interaction between dietary
factors and genetic variants, potentially raising type II error
rates (48).
We conducted a large-scale, gene-diet interaction meta-
analysis in which we investigated the association between
zinc intake (dietary and total) and fasting glucose levels
and the interactions between zinc intake and glucose-,
insulin-, and zinc-related genetic variants on fasting glucose
levels. We showed that total zinc intake (food sources and
supplements), but not zinc from foods alone, is associated
with lower fasting glucose levels in individuals without T2D.
Our ﬁndings suggest that total zinc intake has a stronger
inverse association with fasting glucose levels in indi-
viduals carrying the glucose-raising A allele of rs11558471
SLC30A8 (a b-cell zinc transporter), compared with indi-
viduals carrying the G allele. The current study indicates
that gene-environment interaction analyses can help elu-
cidate our understanding of the biological pathways in-
volved in micronutrient inﬂuences on systemic glucose
homeostasis.
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